🎉 M&A multiples are live!
Check it out!

Artiva Biotherapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Artiva Biotherapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Artiva Biotherapeutics Overview

About Artiva Biotherapeutics

Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).


Founded

2019

HQ

United States of America
Employees

89

Website

artivabio.com

Financials

LTM Revenue $0.2M

LTM EBITDA n/a

EV

-$123M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Artiva Biotherapeutics Financials

Artiva Biotherapeutics has a last 12-month revenue of $0.2M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Artiva Biotherapeutics achieved revenue of $0.3M and an EBITDA of -$64.9M.

Artiva Biotherapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Artiva Biotherapeutics valuation multiples based on analyst estimates

Artiva Biotherapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $33.5M $0.3M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$28.4M -$64.9M XXX XXX XXX
EBITDA Margin -85% -25837% XXX XXX XXX
Net Profit -$58.4M -$27.7M XXX XXX XXX
Net Margin -174% -11034% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Artiva Biotherapeutics Stock Performance

As of April 15, 2025, Artiva Biotherapeutics's stock price is $2.

Artiva Biotherapeutics has current market cap of $47.8M, and EV of -$123M.

See Artiva Biotherapeutics trading valuation data

Artiva Biotherapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$123M $47.8M XXX XXX XXX XXX $-4.98

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Artiva Biotherapeutics Valuation Multiples

As of April 15, 2025, Artiva Biotherapeutics has market cap of $47.8M and EV of -$123M.

Artiva Biotherapeutics's trades at -689.7x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Artiva Biotherapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Artiva Biotherapeutics and 10K+ public comps

Artiva Biotherapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$123M XXX XXX XXX
EV/Revenue -491.3x XXX XXX XXX
EV/EBITDA 1.9x XXX XXX XXX
P/E -0.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 2.2x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Artiva Biotherapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Artiva Biotherapeutics Valuation Multiples

Artiva Biotherapeutics's NTM/LTM revenue growth is -100%

Artiva Biotherapeutics's revenue per employee for the last fiscal year averaged $3K, while opex per employee averaged $0.8M for the same period.

Over next 12 months, Artiva Biotherapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Artiva Biotherapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Artiva Biotherapeutics and other 10K+ public comps

Artiva Biotherapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -99% XXX XXX XXX XXX
EBITDA Margin -25837% XXX XXX XXX XXX
EBITDA Growth 128% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $3K XXX XXX XXX XXX
Opex per Employee $0.8M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 6855% XXX XXX XXX XXX
R&D Expenses to Revenue 20051% XXX XXX XXX XXX
Opex to Revenue 26906% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Artiva Biotherapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Artiva Biotherapeutics M&A and Investment Activity

Artiva Biotherapeutics acquired  XXX companies to date.

Last acquisition by Artiva Biotherapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Artiva Biotherapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Artiva Biotherapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Artiva Biotherapeutics

When was Artiva Biotherapeutics founded? Artiva Biotherapeutics was founded in 2019.
Where is Artiva Biotherapeutics headquartered? Artiva Biotherapeutics is headquartered in United States of America.
How many employees does Artiva Biotherapeutics have? As of today, Artiva Biotherapeutics has 89 employees.
Who is the CEO of Artiva Biotherapeutics? Artiva Biotherapeutics's CEO is Dr. Fred Aslan, M.D..
Is Artiva Biotherapeutics publicy listed? Yes, Artiva Biotherapeutics is a public company listed on NAS.
What is the stock symbol of Artiva Biotherapeutics? Artiva Biotherapeutics trades under ARTV ticker.
When did Artiva Biotherapeutics go public? Artiva Biotherapeutics went public in 2024.
Who are competitors of Artiva Biotherapeutics? Similar companies to Artiva Biotherapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Artiva Biotherapeutics? Artiva Biotherapeutics's current market cap is $47.8M
What is the current revenue of Artiva Biotherapeutics? Artiva Biotherapeutics's last 12-month revenue is $0.2M.
What is the current EV/Revenue multiple of Artiva Biotherapeutics? Current revenue multiple of Artiva Biotherapeutics is -689.7x.
What is the current revenue growth of Artiva Biotherapeutics? Artiva Biotherapeutics revenue growth between 2023 and 2024 was -99%.
Is Artiva Biotherapeutics profitable? Yes, Artiva Biotherapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.